UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Concept and Clinical Evaluation of Carrier‐Mediated Anticancer Agents

The oncologist (Dayton, Ohio), 2008-03, Vol.13 (3), p.248-260

Zamboni, William C.

2008

Volltextzugriff (PDF)

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

Clinical cancer research, 2005-12, Vol.11 (23), p.8230-8234

ZAMBONI, William C

2005

Volltextzugriff (PDF)

Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles

Proceedings of the National Academy of Sciences - PNAS, 2011-01, Vol.108 (2), p.586-591

2011

Volltextzugriff (PDF)

Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer

PloS one, 2013-05, Vol.8 (5), p.e61359

2013

Volltextzugriff (PDF)

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.476-487

2012

Volltextzugriff (PDF)

Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma

ACS applied materials & interfaces, 2020-04, Vol.12 (17), p.19345-19356

2020

Volltextzugriff (PDF)

A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics

Science advances, 2020-07, Vol.6 (29), p.eaay9249-eaay9249

2020

Volltextzugriff (PDF)

Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy

Biomaterials, 2013-11, Vol.34 (33), p.8424-8429

2013

Volltextzugriff (PDF)

Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft

Nanomedicine, 2013-07, Vol.9 (5), p.686-693

2013

Volltextzugriff (PDF)

Factors Affecting the Pharmacology of Antibody-Drug Conjugates

Antibodies (Basel), 2018-02, Vol.7 (1), p.10

2018

Volltextzugriff (PDF)

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

Cancer chemotherapy and pharmacology, 2012-01, Vol.69 (1), p.43-50

2012

Volltextzugriff (PDF)

Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases

Current rheumatology reviews, 2014-04, Vol.10 (1), p.22-34

2014

Volltextzugriff (PDF)

Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study

PloS one, 2017-10, Vol.12 (10), p.e0186018

2017

Volltextzugriff (PDF)

Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems

Pharmaceutics, 2021-01, Vol.13 (1), p.114

2021

Volltextzugriff (PDF)

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective

Antibodies (Basel), 2021-07, Vol.10 (3), p.30

2021

Volltextzugriff (PDF)

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

Journal of liposome research, 2012-09, Vol.22 (3), p.177-192

2012

Volltextzugriff (PDF)

Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer

Molecular pharmaceutics, 2016-06, Vol.13 (6), p.1996-2009

2016

Volltextzugriff (PDF)

Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma

Proceedings of the National Academy of Sciences - PNAS, 2016-02, Vol.113 (8), p.2200-2205

2016

Volltextzugriff (PDF)

Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models

Nanomedicine, 2017-02, Vol.13 (2), p.471-482

2017

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies

Clinical cancer research, 2009-02, Vol.15 (4), p.1466-1472

2009

Volltextzugriff (PDF)

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts

Clinical cancer research, 2007-12, Vol.13 (23), p.7217-7223

2007

Volltextzugriff (PDF)

Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains

Nanomedicine, 2016-10, Vol.12 (7), p.2007-2017

2016

Volltextzugriff (PDF)

Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents

Journal of clinical pharmacology, 2023-11, Vol.63 (S2), p.S85-S102

2023

Volltextzugriff (PDF)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

Antibodies (Basel), 2019-01, Vol.8 (1), p.3

2019

Volltextzugriff (PDF)

Evading Immune Cell Uptake and Clearance Requires PEG Grafting at Densities Substantially Exceeding the Minimum for Brush Conformation

Molecular pharmaceutics, 2014-04, Vol.11 (4), p.1250-1258

2014

Volltextzugriff (PDF)

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(204)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(235)

Erscheinungsjahr

n.n

Thema

Science & Technology
(181)
Life Sciences & Biomedicine
(165)
Humans
(136)
Animals
(98)
Female
(90)
Oncology
(76)
Biological And Medical Sciences
(70)
Medical Sciences
(66)
Pharmacology & Pharmacy
(59)
Male
(56)
Mice
(54)
Pharmacokinetics
(49)
Pharmacology. Drug Treatments
(47)
Antineoplastic Agents
(43)
Antineoplastic Agents - Pharmacokinetics
(42)
Neoplasms - Drug Therapy
(40)
Middle Aged
(39)
Adult
(36)
Camptothecin - Analogs & Derivatives
(33)
Antineoplastic Agents - Administration & Dosage
(31)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Concept and Clinical Evaluation of Carrier‐Mediated Anticancer Agents

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles

Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma

A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics

Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy

Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft

Factors Affecting the Pharmacology of Antibody-Drug Conjugates

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases

Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study

Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer

Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma

Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models

Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts

Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains

Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

Evading Immune Cell Uptake and Clearance Requires PEG Grafting at Densities Substantially Exceeding the Minimum for Brush Conformation

Suchergebnisse filtern